EICHOR
● Completed
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR
Condition: Non-Small Cell Lung Cancer · Sponsor: Spanish Lung Cancer Group
About this study
A Phase III, multicenter, open-label, randomized trial of Erlotinib (Tarceva®) versus chemotherapy in patients with advanced NSCLC with mutations in the Tyrosine Kinase (TK) domain of the EGFR.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (76)
| Centre Hospitalier Universitaire D'Angers | Angers, France | — |
| Hôpital Auguste Morvan | Brest, France | — |
| Centre François Baclesse | Caen, France | — |
| Centre Hospitalier René Dubos | Cergy-Pontoise, France | — |
| Centre Hospitalier Intercommunal | Créteil, France | — |
| Hôpital A. Mignot | Le Chesnay, France | — |
| Centre Hospitalier Du Mans | Le Mans, France | — |
| Centre Oscar Lambret | Lille, France | — |
| Hôpital du Cluzeau | Limoges, France | — |
| Centre Hospitalier Régional | Longjumeau, France | — |
| Centre Hospitalier de Meaux | Meaux, France | — |
| Centre Hospitalier de Mulhouse | Mulhouse, France | — |
+ 64 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00446225